A process for forming amorphous atorvastatin comprising the steps of dissolving atorvastatin in a non-hydroxylic solvent and removing the solvent by freeze-drying as well as processes of dissolving atorvastatin in a hydroxylic solvent with a solubilizing agent or an alkalizing agent or an antioxidant and removing the solvent by freeze-drying to afford amorphous atorvastatin.

Materials and methods for preparing (S)-(+)-3-aminomethyl-5-methyl-hexanoic acid and structurally related compounds via enzymatic kinetic resolution are disclosed.

A process for forming amorphous atorvastatin comprising the steps of dissolving atorvastatin in a non-hydroxylic solvent and removing the solvent by freeze-drying as well as processes of dissolving atorvastatin in a hydroxylic solvent with a solubilizing agent or an alkalizing agent or an antioxidant and removing the solvent by freeze-drying to afford amorphous atorvastatin.

Materials and Methods for preparing (S)-(+)-3-aminomethyl-5-methyl-hexanoic acid and structurally related compounds via enzymatic kinetic resolution are disclosed.

The present invention relates to a class of substituted 124-triazoles of formula (I) with activity as oxytocin antagonists uses thereof processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction particularly premature ejaculation (P.E.).

The invention relates to nicotinamide derivatives of formula (1) and to processes for the preparation of intermediates used in the preparation of compositions containing and the uses of such derivatives. The nicotinamide derivatives according to the present invention are phosphodiesterase-4 inhibitors and are useful in numerous diseases disorders and ( conditions in particular inflammatory allergic respiratory diseases disorders and conditions as well as wounds.

Compounds; pharmaceutically acceptable salts thereof; and stereoisomers of the compound of Formula I and pharmaceutically acceptable salts thereof; are disclosed wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions and methods of treatment are also disclosed.

Atorvastatin lactone is prepared by hydrogenating tert-butyl isopropylidene nitrile to tert-butyl isopropylidene amine and condensing the amine with the diketone of atorvastatin to form acetonide ester. The diol protecting acetonide ester is deprotected to form a diol ester by dissolving the acetonide ester in methanol and treating with an acid. The diol ester is saponified to form a sodium salt. Methanol is removed from the reaction mixture by distillation. The sodium salt is reacidified to the...

The diketone of atorvastatin is prepared by first washing a reaction vessel with a non-ketonic solvent especially tetrahydrofuran to remove water. 4-fluorobenzaldehyde is then reacted with benzylidine isobutyryl acetanilide in the reaction vessel to form 4-fluoro-alpha-(2-methyl-1-oxopropyl)-gamma-oxo-Nbeta-diphenylbenzene-butanainide